Indication · Otolaryngology (ENT)
Tinnitus
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
48
Cleared or approved since 2000
PMA and De Novo
1
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
20
158 device trials in all
Devices
1 devices via De Novo. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- Lenire Tinnitus Treatment Device
Neuromod Devices Limited · De Novo · Combined Acoustic And Electrical External Stimulation Device For The Relief Of Tinnitus · newest 2023
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal TinnitusPivotal-lookingRecruiting
University of Dublin, Trinity CollegeAcademic, hospital or other
NCT07393880 · 100 participants (planned) · Start Jun 30, 2026 · Primary completion Sep 30, 2028
Device: Real NITESGON; Sham NITESGON · For: Tinnitus, Subjective; Tinnitus; Chronic Tinnitus
Sites: Dublin, Ireland
157 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on tinnitus across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.